Breakthrough could herald revolution in treatment of RSV

14 October 2022

A significant late stage trial win lifted GSK (LSE: GSK) stock by around 1.5% in early morning trading on Friday, with the company hailing the result as “truly exceptional.”

The British drugmaker is seeking to develop what could be the first ever respiratory syncytial virus (RSV) vaccine, combining a recombinant antigen with its proprietary AS01E adjuvant.

Enrolling 25,000 people in 17 countries, the AReSVi-006 trial represents a major investment for GSK, in an area which could offer a lucrative return should the firm be the first to market with an approved option.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK